Egret Therapeutics, a clinical-stage biotherapeutics company focused on the treatment of neurological diseases, announced today the completion of its pre-A financing. The funding was led by FAScinate Therapeutics, Inc, a clinical neurological diseases company, with participation from Turret Capital Management and private investors.

Egret Therapeutics is a clinical-stage biotherapeutics company. The company is focused on developing products to address areas of clinical unmet need in neurological diseases.
For more information, visit us at www.egrettherapeutics.com.

Egret Therapeutics Completes Oversubscribed Pre-A Financing Round

Description

Company Information

Egret Therapeutics Completes Oversubscribed Pre-A Financing Round

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information